Purinergic P2X7 receptor antagonists: Chemistry and fundamentals of biological screening

被引：11
|
作者：
Gunosewoyo, Hendra [1 ,2 ]
Coster, Mark J. [3 ]
Bennett, Maxwell R. [2 ]
Kassiou, Michael [1 ,2 ,4 ]
机构：
[1] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia
[2] Brain & Mind Res Inst, Sydney, NSW 2050, Australia
[3] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Nathan, Qld 4111, Australia
[4] Univ Sydney, Discipline Med Radiat Sci, Sydney, NSW 2006, Australia
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2009年 / 17卷 / 14期
关键词：
P2X7; antagonists; Cytokine release; Rational drug design; LL-37; IN-VITRO ACTIVITY; INTERLEUKIN-1-BETA RELEASE; POLYMYXIN-B; POTENT; DISCOVERY; PEPTIDE; LL-37; PAIN; TAIL;
D O I：
10.1016/j.bmc.2009.05.083
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The purinergic P2X(7) receptor is a unique member of the ATP-gated P2X family. This receptor has been implicated in numerous diseases and many structurally diverse ligands have been discovered via high throughput screening. This perspective will attempt to highlight some of the most recent key findings in both the biology and chemistry. (C) 2009 Elsevier Ltd. All rights reserved.
引用
下载
收藏
页码：4861 / 4865
页数：5
相关论文
共 50 条
  • [21] Defiency of Purinergic Receptor P2X7 Reduces Atherosclerosis in Mice
    Stachon, Peter
    Heidenreich, Adrian
    Merz, Julian
    Hoppe, Natalie
    Bode, Christoph
    Idzko, Marco
    Zirlik, Andreas
    CIRCULATION, 2016, 134
  • [22] The contribution of monocytes and the purinergic receptor, P2X7, in MS relapse
    Monif, M.
    O'Brien, T.
    Hamilton, J.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 837 - 838
  • [23] Purinergic P2X7 receptor:: A pivotal role in inflammation and immunomodulation
    Di Virgilio, F
    Falzoni, S
    Mutini, C
    Sanz, JM
    Chiozzi, P
    DRUG DEVELOPMENT RESEARCH, 1998, 45 (3-4) : 207 - 213
  • [24] Associations Between the Purinergic Receptor P2X7 and Leprosy Disease
    Souza, Rebeka da Conceicao
    de Souza, Thais Louvain
    Ferreira, Cristina dos Santos
    Nascimento, Leticia Silva
    Nahn, Edilbert Pellegrini
    Peixoto-Rangel, Alba Lucinia
    FRONTIERS IN GENETICS, 2021, 12
  • [25] The P2X7 purinergic receptor: from physiology to neurological disorders
    Skaper, Stephen D.
    Debetto, Patrizia
    Giusti, Pietro
    FASEB JOURNAL, 2010, 24 (02): : 337 - 345
  • [26] Purinergic P2X7 receptor as a potential therapeutic target in depression
    Qi, Wang
    Jin, Xiang
    Guan, Wei
    BIOCHEMICAL PHARMACOLOGY, 2024, 219
  • [27] Role of the purinergic receptor P2X7 in Alzheimer's disease
    Delarasse, Cecile
    PURINERGIC SIGNALLING, 2014, 10 (04) : 703 - 703
  • [28] Novel Series of Dihydropyridinone P2X7 Receptor Antagonists
    Lopez-Tapia, Francisco
    Walker, Keith A. M.
    Brotherton-Pleiss, Christine
    Caroon, Joanie
    Nitzan, Dov
    Lowrie, Lee
    Gleason, Shelley
    Zhao, Shu-Hai
    Berger, Jacob
    Cockayne, Debra
    Phippard, Deborah
    Suttmann, Rebecca
    Fitch, William L.
    Bourdet, David
    Rege, Pankaj
    Huang, Xiaojun
    Broadbent, Scott
    Dvorak, Charles
    Zhu, Jiang
    Wagner, Paul
    Padilla, Fernando
    Loe, Brad
    Jahangir, Alam
    Alker, Andre
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (21) : 8413 - 8426
  • [29] Effects of antagonists at the human recombinant P2X7 receptor
    Chessell, IP
    Michel, AD
    Humphrey, PPA
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (06) : 1314 - 1320
  • [30] Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism
    McInnes, I. B.
    Cruwys, S.
    Bowers, K.
    Braddock, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (06) : 878 - 882
12345